This event is free of commercial bias, and industry employees are prohibited from attending.

This activity has been planned and implemented in accordance with the accreditation requirements of the Washington State Medical Association through the joint providership of EvergreenHealth and the National MS Society. EvergreenHealth is accredited by the WSMA to provide continuing medical education for physicians. EvergreenHealth designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 7.0 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

KEYNOTE SPEAKER

Jeffrey Cohen, MD, Neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic in Cleveland, OH. Dr. Cohen has a large clinical practice devoted primarily to the care of patients with multiple sclerosis and related disorders. In addition, he is Director of the Experimental Therapeutics Program and has been involved in various capacities in a large number of clinical trials developing new therapies for multiple sclerosis.

“New Diagnostic Criteria for MS Diagnosis”
LEARNING OBJECTIVES

• Describe available resources on the Clinical Care Network for clinicians and patients that will contribute to optimal care of the MS patient.
• Describe the 2017 revision to the McDonald criteria.
• Identify the most common diagnoses and syndromes misdiagnosed as MS and cite common contributors to MS misdiagnosis.
• Recognize the most common disorders on the differential diagnosis of MS.
• Describe metrics of neuroplasticity and the evidence outlining the benefits of exercise.
• Apply neuroplasticity principles to design a patient centered rehabilitation plan that is evidence based and will maximize the restorative potential and promote lifelong health and wellness.
• Describe and utilize pharmacologic and non-pharmacologic interventions in the management of spasticity in MS.
• Identify known and novel benefits associated with the use of MS therapies, and the mitigating strategies used to minimize those risks to maximize patient outcomes.
• Identify known and novel benefits associated with the use of MS therapies, and the mitigating strategies used to maximize those benefits.
• Describe how to manage urinary incontinence, urgency, hesitancy, and retention, and discuss the risk/benefits of various treatments, including bladder BOTOX.
• Apply concepts from most clinically impactful research achievements of the past year.
• Connect with MS providers to discuss difficult cases and seek consensus on treatment options for difficult MS cases.

SUMMIT AGENDA

7:30 a.m. Registration and Continental Breakfast
8:00 a.m. Welcome & Update on National MS Society Anne Cross, MD
8:20 a.m. New Diagnostic Criteria for MS Diagnosis Jeffrey Cohen, MD
9:30 a.m. MS Misdiagnosis
9:45 a.m. MS Differential Diagnosis Emily Evans, MD
10:00 a.m. BREAK
10:15 a.m. Principles of Neuroplasticity Robert Motl, PhD
11:00 a.m. Rehabilitation and Neuroplasticity, Elissa Held Bradford, PT, PhD, NCS, MSCS
11:30 a.m. Spasticity Management Amy Rauchway, DO Spencer Cotterell, DO
12:00 p.m. LUNCH
1:00 p.m. A Practical Guide to Disease Modifying Therapies Salim Chahin, MD
1:45 p.m. MS: Bladder Issues and Treatment H. Henry Lai, MD
2:30 p.m. Top 5 Most Impactful Research Findings in 2017 Gregory Wu, MD, PhD
3:00 p.m. BREAK
3:15 p.m. Case Presentations
4:30 p.m. ADJOURN